SITE004-0041

SITE004 (DEU) › SITE004-0041

SITE004-0041

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE004 (DEU) · Dr. Tanaka
consented 2025-10-11

enrolled

AEs

4

Serious

0

Dropout signal

–

Adverse events

4

Grade 1 Alopecia — outcome: UNKNOWN; onset 2023-01-18 (study day 267); relationship: not assessed

mild assessed

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-12-17 (study day 235); relationship: not assessed

moderate assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-05-30 (study day 34); relationship: NOT RELATED

mild assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-05-30 (study day 34); relationship: RELATED

moderate assessed

Data queries

1

2 adverse event records for SITE004-0041 share preferred term Anaemia and onset 2025-12-04. Duplicate entry; the first record (entered 2025-12-04) is kept.

AE.duplicate[Anaemia 2025-12-04] closed